Jalal Eldin Abdel Wahab, Tombayoglu Dilara, Butz Laura, Affinati Alison, Meral Rasimcan, Ontan Mehmet Selman, Walkovich Kelly, Westerhoff Maria, Innis Jeffrey W, Parikh Neehar D, Oral Elif A
1Division of Metabolism, Endocrinology and Diabetes (MEND), Department of Internal Medicine Brehm Center for Diabetes, Michigan Medicine, University of Michigan, 1000 Wall Street, Room 5313, Ann Arbor, MI 48105 USA.
2Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Clin Diabetes Endocrinol. 2019 Jul 9;5:9. doi: 10.1186/s40842-019-0082-y. eCollection 2019.
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) is a rare syndrome with unknown etiology. Metabolic abnormalities are not known to be part of the syndrome. We present one of the oldest cases reported in the literature, who developed severe metabolic abnormalities and hepatic disease suggesting that these features may be part of the syndrome.
A 27-year-old woman, diagnosed with ROHHAD syndrome at age 15, who previously developed diabetes insipidus, growth hormone deficiency, hyperprolactinemia, and hypothyroidism in her first decade of life. This was followed by insulin resistance, NAFLD, liver fibrosis, and splenomegaly before age 14 years. Her regimen included a short course of growth hormone, and cyclic estrogen and progesterone. Her metabolic deterioration continued despite treatment with metformin. Interestingly, she had a favorable response to liraglutide therapy despite having a centrally mediated cause for her obesity. At age 26, a 1.6 cm lesion was found incidentally in her liver. Liver biopsy showed hepatocellular carcinoma which was successfully treated with radiofrequency ablation.
Metabolic abnormalities, Insulin resistance and fatty liver disease are potentially part of the ROHHAD syndrome that may develop over time. GLP1 agonists were reasonably effective to treat insulin resistance and hyperphagia. Patients with ROHHAD may benefit from close follow up in regards to liver disease.
快速发作性肥胖伴下丘脑功能障碍、通气不足和自主神经失调(ROHHAD)是一种病因不明的罕见综合征。代谢异常是否为该综合征的一部分尚不清楚。我们报告了文献中记载的年龄最大的病例之一,该患者出现了严重的代谢异常和肝脏疾病,提示这些特征可能是该综合征的一部分。
一名27岁女性,15岁时被诊断为ROHHAD综合征,在其生命的第一个十年中曾患尿崩症、生长激素缺乏症、高催乳素血症和甲状腺功能减退症。14岁前出现胰岛素抵抗、非酒精性脂肪性肝病(NAFLD)、肝纤维化和脾肿大。她的治疗方案包括短期使用生长激素,以及周期性使用雌激素和孕激素。尽管使用二甲双胍治疗,她的代谢仍持续恶化。有趣的是,尽管她肥胖的原因是中枢介导的,但她对利拉鲁肽治疗有良好反应。26岁时,她肝脏中偶然发现一个1.6厘米的病灶。肝脏活检显示为肝细胞癌,通过射频消融成功治疗。
代谢异常、胰岛素抵抗和脂肪性肝病可能是ROHHAD综合征随时间发展的潜在组成部分。胰高血糖素样肽1(GLP1)激动剂对治疗胰岛素抵抗和食欲亢进相当有效。ROHHAD患者可能会从肝病密切随访中获益。